Université Pierre et Marie Curie.
AIDS. 2013 May 15;27(8):1356-9. doi: 10.1097/QAD.0b013e32836138d0.
The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12 IU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (n = 9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12 IU/ml at W24 (P < 0.001). No grade 3-4 dermatological side-effects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients.
替拉瑞韦（TVR）在 20 名大多患有肝硬化的、先前使用聚乙二醇干扰素和利巴韦林（PR）治疗失败的 HIV-丙型肝炎基因型 1（HCV-G1）感染患者中的疗效和耐受性得到了检验。在 W2 时，35.3%的患者的 HCV-RNA 低于 12IU/ml，W4 时为 55.0%，W12 时为 65.0%，W24 时为 55.0%。所有发生病毒学失败的患者（n=9）均出现 V36M/R155K 突变。早期病毒学应答是 W24 时 HCV-RNA 低于 12IU/ml 的决定因素（P<0.001）。未报告任何 3-4 级皮肤副作用。TVR-PR 三联疗法在治疗困难的 HIV-HCV-G1 患者中似乎非常有效且耐受良好。
